



[Science](#)[Education](#)[Patient Care](#)

[Our Society](#)[Our Mission, Vision & Values](#)[EBMT Membership 2025](#)[Organisational Structure 2025](#)[Financial Highlights 2025](#)[EBMT Partners](#)

## Breadcrumb

1. [Home](#)

## Entity Print



Olaf Penack

TCWP Chair (ELECTED APRIL 2025, PREVIOUS CHAIR: Zinaida Perić)  
Germany

## Major achievements

Despite all our efforts and progress in our field, significant clinical challenges remain, which TCWP addresses by optimising current management and improving the evidence base for developing new treatment strategies.

In 2025, we:

- improved scientific and educational output and quality by expanding collaboration with other EBMT Working Parties.
- strengthened our partnerships with the EBMT Nurses Group. We integrated nursing-specific content into our scientific and educational activities.
- intensified collaboration with patient representatives to ensure patient-centred scientific action.
- planned, conducted, analysed, and published studies on complications following stem cell transplantation and cellular therapies.
- published evidence-based recommendations for the clinical management of patients with complications following CAR-T cell therapy.
- organised two educational Meetings:
  - Complications post CAR-T Cell Therapy in Paediatric and Adult Patients, 16-18 January 2025, Malaga, Spain
  - Transplant Complications Working Party Educational Meeting, 1-3 October 2025, Dubrovnik, Croatia

Continued to build up and consolidate the TCWP team, which will further improve effectiveness and scientific output in the future.



TCWP team, Dubrovnik, Croatia

## Principal research studies

[Severity and response criteria in transplant-associated thrombotic microangiopathy](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[All diseases](#)

[Group](#)

[Complications Working Party \(CWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Ivan Moiseev](#)

[Treatment and outcome of sHLH after allogeneic hematopoietic stem cell transplantation](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[All diseases](#)

[Group](#)

[Complications Working Party \(CWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Polona Novak](#)

[CAR-T cell outcomes in patients with comorbidities](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[All diseases](#)

[Group](#)

[Complications Working Party \(CWP\)](#)

[Type of treatment](#)

[CAR T](#)

[Principal investigator](#)

[Olaf Penack](#)

[Long-term outcomes of PTCy vs. ATG in MRD, MUD, MMUD](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[All diseases](#)

[Group](#)

[Complications Working Party \(CWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Hélène Schoemans](#)

[Multicentric evaluation of CAR-T cell induced pseudoprogression prevalence](#)

[\(PrevCARTiPP\)](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[All diseases](#)

[Group](#)

[Complications Working Party \(CWP\)](#)

[Type of treatment](#)

[CAR T](#)

[Principal investigator](#)

[Friedrich Stoelzel](#)

## **Key publications**

[2025](#)

[Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study](#)

[Group](#)

[Complications Working Party \(CWP\)](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[1st listed author](#)

[Guillermo Ortí](#)

[Journal](#)

[Leukemia.](#)

[2025](#)

[Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee](#)

[Group](#)

[Complications Working Party \(CWP\)](#)

[Practice Harmonisation and Guidelines Committee](#)

[1st listed author](#)

[Charlotte E Graham](#)

[Journal](#)

[Lancet Oncol.](#)

[2025](#)

[Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee](#)

[Group](#)

[Complications Working Party \(CWP\)](#)

[Practice Harmonisation and Guidelines Committee](#)

[1st listed author](#)

[Guillermo Ortí](#)

[Journal](#)

[Bone Marrow Transplant.](#)

[2025](#)

[GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party](#)

[Group](#)

[Complications Working Party \(CWP\)](#)

[1st listed author](#)

[Olaf Penack](#)

[Journal](#)

[Leukemia.](#)

[2025](#)

[Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party](#)

[Group](#)

[Complications Working Party \(CWP\)](#)

[1st listed author](#)

[Nico Gagelmann](#)

[Journal](#)

[Blood Cancer J.](#)

[See the full list of the TCWP 2025 publications](#)



## Indicators

	<b>2023</b>	<b>2024</b>	<b>2025</b>
<b>Impact factor</b>	44.70	99.90	<b>105.50</b>
<b>Oral presentations</b>	1	4	<b>2</b>
<b>Poster presentations</b>	9	4	<b>1</b>
<b>Educational events</b>	1	2	<b>2</b>

## Major educational events



[Event](#)

## **51st Annual Meeting of the FBMT**



[Event](#)

## Transplant Complications Working Party Educational Meeting



ia

Event

### **\*RESCHEDULED\* Complications post CAR-T Cell Therapy in Paediatric and Adult Patients**

Jan 16, 2025 - Jan 18, 2025 / Málaga, Spain

Discover more

VISIT THE TCWP WEBPAGE